No Clinically Significant Interaction Between Levetiracetam and Dexamethasone Suppression Testing
Levetiracetam (Keppra) does not interfere with the dexamethasone suppression test (DST) through pharmacokinetic mechanisms and can be safely continued during diagnostic evaluation for Cushing's syndrome.
Pharmacokinetic Evidence
The FDA-approved drug label for levetiracetam explicitly states that it is "unlikely to produce, or be subject to, pharmacokinetic interactions" 1. Specifically:
- Levetiracetam and its major metabolite are neither inhibitors of nor high affinity substrates for human liver cytochrome P450 isoforms, including CYP3A4, which metabolizes dexamethasone 1
- Levetiracetam does not affect UDP-glucuronidation enzymes or epoxide hydrolase 1
- Levetiracetam circulates largely unbound (<10% bound) to plasma proteins, making protein-binding displacement interactions unlikely 1
Clinical Context for DST
When performing a dexamethasone suppression test for suspected Cushing's syndrome, the primary concern is medications that alter dexamethasone metabolism through CYP3A4 induction or inhibition 2, 3. The 2008 Endocrine Society guidelines emphasize that drugs modifying dexamethasone metabolism can affect test results 2. A 2020 review confirms that CYP3A4 interactions are the major concern for DST accuracy 3.
Since levetiracetam does not interact with CYP3A4, it will not alter dexamethasone levels or suppress cortisol inappropriately.
Comparison to Other Antiepileptic Drugs
Unlike enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine, phenobarbital), levetiracetam does not induce hepatic enzymes 1. The FDA label confirms that levetiracetam had no effect on phenytoin pharmacokinetics and was not affected by other antiepileptic drugs 1. This distinguishes it from traditional antiepileptic medications that would accelerate dexamethasone metabolism and potentially cause false-negative DST results.
Practical Recommendations
- Continue levetiracetam during DST without dose adjustment
- Use standard DST protocols: 1-mg overnight test with cortisol cutoff >5.0 µg/dL for subclinical Cushing's syndrome screening 4, or 48-hour low-dose DST (0.5 mg every 6 hours) with cortisol cutoff >1.8 µg/dL 2
- If performing DST in patients on multiple medications, measure dexamethasone levels if false-positive results are suspected based on clinical context 5
Important Caveat
While levetiracetam does not pharmacokinetically interfere with DST, one in vitro study found that levetiracetam (along with dexamethasone) affected protoporphyrin IX production in glioblastoma cells 6. However, this laboratory finding has no relevance to DST interpretation or cortisol metabolism and should not influence clinical decision-making regarding DST performance.